Medtronic’s Resolute Integrity stent outperforms rival in new trial

Medtronic has announced the results of a new clinical trial which underline the benefits its Resolute Integrity drug-eluting stent (DES) can offer over rival devices.

The stent was recently assessed in Dutch Peers, a head-to-head, randomised, controlled trial of third-generation durable-polymer DES offerings for the treatment of coronary artery disease in an all-comers patient population.

When compared to another leading device, it was found that Medtronic's device performed similarly on all measures except longitudinal strength – typically, a weakness of this type of stent – with the Resolute Integrity offering significant advantages in this regard.

Lead author Clemens von Birgelen, professor of cardiology at the University of Twente in the Netherlands, said: "A potential trade-off with the novel, flexible designs of third-generation stent platforms was thought to be reduced longitudinal device stability. However, our study did not find such a trade-off with the Resolute Integrity DES."

This comes after the company also recently reported positive data from Symplicity HTN-2, a study assessing the long-term benefits offered by its Symplicity renal denervation system.